SciClone Pharmaceuticals, Inc. (SCLN) news stock charts
SciClone Pharmaceuticals, Inc. (SCLN) Investment Summary:
SciClone Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases. We are positioned to grow our two assets, a biotechnology business focused on developing late-stage products for cancer and viral infectious diseases for the United States and Europe, and SciClone China, our pharmaceutical business which generates important cash flow to fund its growth and significantly contributes to the funding of our biotechnology business. Our strategy is to in-license late-stage clinical products and develop them for commercialization in the United States, Europe, and the People’s Republic of China, one of the world’s fastest growing pharmaceutical markets. Our lead product ZADAXIN®, our brand of thymalfasin, is approved in select international markets and is one of the largest selling imported drugs in China today, measured in revenue. For the U.S. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f13%2f0001193125-08-055606.html#FIS_BUSINESS"SCICLONE PHARMACEUTICALS INC (SCLN:NASDAQ)
Snapshot of SCICLONE PHARMACEUTICALS INC (SCLN)
|
OPEN
$3.70
|
PREVIOUS CLOSE
$3.75
|
|
|
DAY HIGH
$3.71
|
DAY LOW
$3.65
|
|
|
52 WEEK HIGH
09/1/09 - $5.33
|
52 WEEK LOW
03/23/09 - $1.21
|
|
|
MARKET CAP
174.6M
|
AVERAGE VOLUME 10 D
589.4K
|
|
|
EPS TTM
$0.25
|
SHARES OUTSTANDING
47.3M
|
|
|
SCLN Does Not Pay Dividends
|
P/E TTM
14.8x
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for SCICLONE PHARMACEUTICALS INC (SCLN)
SciClone Pharmaceuticals, Inc. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on March 16, 2010).
SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. Revenues for the fourth quarter of 2009 grew to $18.1 million, or 18% compared to the fourth quarter of 2008. Net income was $2.4 million or $0.05 per share, compared with a net loss of $3.1 million or $0.07 per share in the fourth quarter of 2008, both on a basic and diluted basis. Income from operations was $2,596,000 against loss from operations of $3,062,000 for the same period of the last year. Income before provision for income tax was $2,613,000 against loss before provision for income tax of $3,009,000 for the same period of the last year. For the year ended December 31, 2009, total revenues increased by 34% to $72.4 million, compared with revenues of $54.1 million for the year ended December 31, 2008. Net income was $11.9 million, or $0.26 and $0.25 per dilutedshare on a basic and diluted basis, respectively, compared with a net loss of $8.3 million or $0.18 per share for the year ended December 31, 2008, both on a basic and diluted basis. Income from operations was $12,594,000 against loss from operations of $8,434,000 for the same period of the last year. Income before provision for income tax was $12,586,000 against loss before provision for income tax of $7,873,000 for the same period of the last year. The company anticipates 2010 revenues of between $82 and $85 million, an increase of approximately 15% over 2009. SciClone expects its revenue growth to be driven by the sales of ZADAXIN, principally to China. The Company also anticipates earnings per share for the full year 2010 to be between $0.31 and $0.35.
SciClone Pharmaceuticals, Inc. announced that they will report Q4, 2009 results on 03/02/2010
SciClone Pharmaceuticals, Inc. financial resources
SCLN Competitors
| Company | Last | Change |
| Access Pharmaceuticals Inc | $2.46 USD | -0.13 |
| InterMune Inc | $40.67 USD | -0.11 |
| Migenix Inc | C$0.06 CAD | 0.00 |
| Vertex Pharmaceuticals Inc | $42.62 USD | -0.105 |
| XenoPort Inc | $8.69 USD | -0.07 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | SCLN | Industry Range |
| Price/Earnings | 14.9x |
|
| Price/Sales | 2.4x |
|
| Price/Book | 3.3x |
|
| Price/Cash Flow | 14.9x |
|
| TEV/Sales | 2.0x |
|
|
SCLN |
||
SCLN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About SciClone Pharmaceuticals, Inc.
SCICLONE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Read article
SciClone Pharma reports 4Q profit on sales
Read article
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates
Read article
SciClone Pharmaceuticals to Present at Three Investor Conferences in March
Read article
UPDATE - SciClone Q4 beats Street; forecasts 2010 EPS above view
Read article
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Read article
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates
Read article
SciClone Pharma reports 4Q profit on sales
Read article
SciClone Pharmaceuticals to Present at Three Investor Conferences in March
Read article
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 2, 2010
Read article
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 2, 2010
Read article
SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine
Read article
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
Read article
SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine
Read article
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
Read article
SciClone drug strengthens swine flu shot in tests
Read article
SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
Read article
UPDATE - SciClone says adjuvant raises H1N1 vaccine response
Read article
SciClone Provides 2009 Financial Update and Initial 2010 Sales Revenue Guidance
Read article
UPDATE - SciClone forecasts '10 rev above mkt view
Read article